Comparative Pharmacology
Head-to-head clinical analysis: EGATEN versus HYDROXYSTILBAMIDINE ISETHIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EGATEN versus HYDROXYSTILBAMIDINE ISETHIONATE.
EGATEN vs HYDROXYSTILBAMIDINE ISETHIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triclabendazole inhibits tubulin polymerization by binding to the colchicine binding site on beta-tubulin, leading to disruption of microtubule formation and paralysis/death of susceptible parasites, particularly Fasciola species.
Hydroxystilbamidine isethionate is an antiprotozoal agent that inhibits nucleic acid synthesis and disrupts polyamine metabolism by binding to DNA and RNA, particularly in kinetoplasts of Leishmania species.
10 mg/kg orally as a single dose, with food; for fascioliasis, 10 mg/kg orally three times daily for 3 days.
2-4 mg/kg/day intravenously every 24 hours for visceral leishmaniasis; 2-4 mg/kg intramuscularly every 24 hours for cutaneous leishmaniasis.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 8-12 hours in severe hepatic impairment. Clinical context: supports once-daily dosing.
Terminal half-life: 24-48 hours; clinically, elimination is multiphasic with a slow tissue redistribution phase, requiring cautious dosing to avoid accumulation.
Primarily fecal (90% as metabolites); renal excretion of unchanged drug is negligible (<1%).
Renal: 10-15% as unchanged drug; biliary/fecal: 80-90% as metabolites and unchanged drug; negligible glomerular filtration due to high protein binding; prolonged presence in tissues.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent